NCT07799675Not yet recruiting
Telerehabilitation in Pulmonary Arterial Hypertension
Efficacy, Safety and Effect on the Inflammatory State of a Telerehabilitation Program in Patients With Hypertension Pulmonary Artery
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
Context: Pulmonary arterial hypertension (PAH) causes severe exercise intolerance and reduced quality of life, while access to supervised rehabilitation remains limited. Objective: Evaluate the safety, feasibility, and clinical effects of an 8-week structured home-based telerehabilitation program in stable PAH patients. Methods: A multicenter, prospective, single-arm study including 34 adults with Group 1 PAH (WHO functional class II-III) performing three weekly exercise sessions via a digital platform. Outcomes: The primary endpoint is peak oxygen consumption (VO₂peak) via cardiopulmonary exercise testing, alongside 6-minute walk distance, quality of life questionnaires, inflammatory biomarkers, and safety tracking.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 13 Aug 2026
- Start date
- 30 Aug 2026
- Primary completion date
- 1 Jul 2029
- Lead sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- NCT number
- NCT07799675
What you commit to
- Study type: Interventional
- Planned participants: 34
- From 30 Aug 2026 to the primary completion date, 1 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cognitive impairment or psychiatric disorders preventing comprehension or use of the telerehabilitation program.
Other
- Acute cardiorespiratory instability or medical contraindication to physical exercise.
- Simultaneous participation in another interventional clinical trial.
Who the study is looking for
- Confirmed diagnosis of stable pulmonary arterial hypertension (PAH).
- Age 18 years or older.
- Ability to use a smartphone or mobile application for the telerehabilitation program.
- Signed informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| FIMABIS Coordinator of this site? Confirm its status | Málaga | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.